PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

Completed · Phase 3

Conditions studied: Normal Pressure Hydrocephalus

In brief

This study will determine the level of association between the quantitative estimates of brain uptake of \[18F\]flutemetamol and the quantitative immunohistochemical estimates of amyloid levels in biopsy samples previously obtained during shunt placement in patients who have normal pressure hydrocephalus (NPH).

Key facts

Study ID

NCT01053312

Run by

GE Healthcare

People needed

7

Starts

2009-12-01

Expected to finish

2010-08-01

Last updated by the study team

2012-06-11

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject is 50 years old or older.
• The subject has had a frontal lobe cortical biopsy adequate for the detection and quantitation of amyloid.
• Informed consent has been signed and dated by the subject/and/or subjects' legally acceptable representative, if applicable, in accordance with local regulations.

You may not qualify if…

• The subject has a contraindication for MRI or PET.
• The subject has a known or suspected hypersensitivity/allergy to [18F]flutemetamol.
• The subject has participated in any clinical study using an investigational agent within 30 days of dosing.

Where it is running

• GE Healthcare — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.